Literature DB >> 20670105

Recovery of platelet factor 4 (PF-4) and beta-thromboglobulin (beta-TG) plasma concentrations during remission in patients suffering from atopic dermatitis.

Alicja Kasperska-Zajac1, Kasperska-Zajac Alicja.   

Abstract

Our previous study has for the first time demonstrated that atopic dermatitis (AD) patients show enhanced plasma concentrations of PF4 and beta-TG. In addition, it has been suggested that chemokines may be the markers of AD severity. The aim of this study was to determine whether enhanced platelet activation in active AD withdraws when the disease reaches the clinical remission stage. Plasma PF-4 and beta-TG concentrations were studied in 10 AD patients and in 23 healthy controls. Patients were examined twice: first, during the active period, and next, during the clinical remission lasting for at least 6 months. Plasma PF-4 and beta-TG concentrations in patients upon AD remission were significantly lower as compared to active AD and did not differ significantly from the healthy subjects. Enhanced platelet activation is a transient phenomenon accompanying active AD and disappears during clinical remission. As with earlier data, the findings point to platelet activity in AD increasing during flare, falling following therapy and normalizing upon remission.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20670105     DOI: 10.3109/09537104.2010.493247

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  3 in total

1.  Platelets: essential components of the immune system.

Authors:  Ramadan A Ali; Leah M Wuescher; Randall G Worth
Journal:  Curr Trends Immunol       Date:  2015

Review 2.  Specific immunotherapy in atopic dermatitis.

Authors:  Jungsoo Lee; Chang Ook Park; Kwang Hoon Lee
Journal:  Allergy Asthma Immunol Res       Date:  2014-11-25       Impact factor: 5.764

3.  Increased plasma concentration of vascular endothelial growth factor in patients with atopic dermatitis and its relation to disease severity and platelet activation.

Authors:  E Koczy-Baron; J Jochem; A Kasperska-Zajac
Journal:  Inflamm Res       Date:  2012-08-23       Impact factor: 4.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.